Optimal dosing and monitoring guidance1

Dosing guidelines

1. Initiate: 150 mg BID taken with or without food 2. Titrate: individualized to achieve UFC normalization 3. Maintain: flexible maintenance dosing
1. Initiate: 150 mg BID taken with or without food 2. Titrate: individualized to achieve UFC normalization 3. Maintain: flexible maintenance dosing

Clinically driven monitoring

Before initiating treatment

  • Conduct baseline liver tests (ALT, AST, and total bilirubin)
  • Obtain a baseline ECG
  • Correct hypokalemia and hypomagnesemia

Continued monitoring

  • Conduct an ECG before each dose increase. After a stable dosage is established, monitor routinely for an effect on the QT interval
  • Monitor 24-hour UFC, morning serum or plasma cortisol, and patient’s signs and symptoms for hypocortisolism periodically during Recorlev® treatment

Liver tests

  • Serious hepatotoxicity has been reported in patients receiving Recorlev, and therefore frequent monitoring of liver tests is recommended
  • Monitor liver enzymes and bilirubin weekly for at least 6 weeks after starting Recorlev, every 2 weeks for the next 6 weeks, monthly for the next 3 months, and then as clinically indicated
  • After any dose interruption or dose increase, monitor on a weekly basis until a stable dosage is achieved

See Full Prescribing Information for dosage management and modification across AST/ALT and total bilirubin values.

contact-shape

A clinical pharmacist is available to support you in the management of monitoring and dose modifications.

Call 1-844-444-RCLV (7258) for support

ALT=alanine aminotransferase; AST=aspartate aminotransferase; BID=twice daily; ECG=electrocardiogram; UFC=urinary free cortisol.

Reference: 1. Recorlev. Prescribing Information. Xeris Pharmaceuticals, Inc; 2021.